Welcome and Introductions
Overview of Disease Burden in R/R MCL
Role of Currently Available Irreversible Covalent BTK Inhibitors in MCL
A New Era: Emerging Roles of Reversible Noncovalent BTKis in MCL
Clinical Pearls and Insights: Regional Perspectives
Case Discussions, Key Takeaways, and Audience Question and Answer Session
Julie M. Vose, MD, MBA
Chief, Division of Oncology and Hematology
Neumann M. and Mildred E. Harris Professor
Department of Internal Medicine
University of Nebraska Medical Center
Marco Ladetto, MD
Dipartimento di Medicina Traslazionale
Università del Piemonte Orientale
Vercelli/Novara/Alessandria, Piedmont, Italy
Director of Hematology Oncology
AO SS Antonio E Biagio e Cesare Arrigo
Alessandria, Piedmont, Italy
Max Topp, MD
Head of the Hematology
Med. Klinik und Poliklinik II
Zentrum Innere Medizin
This program will provide expert perspectives on evidence-based clinical integration of new and emerging BTK inhibitors into the treatment algorithm and personalized care of patients with relapsed or refractory MCL, including discussions of the regional impact of the latest data, and strategies for the optimal selection and sequencing of BTK inhibitors, and management of the adverse events associated with these agents from a global point of view.
The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in selecting individualized treatments for patients with relapsed/refractory MCL.
This globally focused educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat and manage patients with mantle cell lymphoma.
Upon completion of this activity, participants should be able to:
- Evaluate emerging BTK inhibitor data in the treatment of MCL considering the potential impact of safety and efficacy results on clinical practice
- Plan BTKi-based therapeutic strategies for patients with R/R MCL, taking into consideration global indications and recent practice-changing clinical trial results
- Select and sequence therapy for patients with MCL who have developed resistance to or intolerance of covalent BTKi-based therapy to optimize clinical outcomes
- Identify patients with MCL who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.